Figure 4.
Distribution of continuous outcomes, non-HDL cholesterol and systolic blood pressure levels, at 6-month (switching) and 12-month visits*. *6-month visit data include all patients switched to the FDC and 12-month study visit include all patients switched to FDC and retained in the study at 12 months, in an intention-to-treat analysis. FDC, fixed dose combination; non-HDL, non high-density lipoprotein.
